Skyepharma Press Releases

Skyepharma to communicate nutraceutical CDMO capabilities at Vitafoods Europe 2019


Skyepharma to communicate nutraceutical CDMO capabilities at Vitafoods Europe 2019


Skyepharma Logo 150 x 43

Press Release |Skyepharma Production S.A.S.

APRIL 26, 2019

Saint-Quentin-Fallavier, France: – Oral dosage specialist Skyepharma Productions S.A.S. (Skyepharma) will again be represented at the upcoming Vitafoods Europe exhibition in Geneva.

Skyepharma also attended Vitafoods last year in line with its status as a key player in the field of development, commercial manufacturing and packaging of complex oral solid dosage forms.

Skyepharma will take advantage on the event’s exciting networking opportunities to communicate its tailored capabilities for pharmaceutical, nutraceuticals & food supplement development and manufacturing.

Growing nutraceuticals markets

As a CDMO, Skyepharma can help clients from the early development stage to the commercial manufacturing and packaging, offering agility and flexibility that are key added values for the nutraceuticals & food supplement sectors, delivering accelerated times to market.

Skyepharma will be represented in Geneva by its Business Development Consultant, Jeroen Van Egmond.

Mr. Van Egmond commented: “We are very pleased to be returning to this excellent event that reflects the growing market for food supplements with many opportunities for development of innovative tablet or capsules food supplement, from early stage formulation development up to commercial manufacturing and packaging.”

State-of-the-art technologies

“Multi-layer tablet, tab-in-tab, press coated tablet and even chewing gum tablets are of great interest for our partners in the increasingly competitive nutraceuticals and food supplements environments and our technologies and state-of-the-art equipment are well adapted for these sectors,” said Mr. Van Egmond.

“We can also offer the strong development skills that are so important to fast prototyping and reduced time to market,” he added.

Skyepharma’s appearance at Vitafoods Europe will closely coincide with an article to appear in France’s Actu Labo magazine that highlights Skyepharma’s capacity to develop food supplements for its partners.

Business transformation

Skyepharma will also be communicating the significant changes that have taken place within the organisation as part of its transformation to a full CDMO, including the recent formation of a dedicated Customer Service department.

Since July 2016, Skyepharma has been transforming its processes and facilities to support its mission to become an end-to-end contract CDMO, providing services extending from early stage development and manufacturing through to packaging, serialization and aggregation.

It is now accepting requests via LinkedIn and email to set up face to face meetings at Vitafoods 2019.

About Skyepharma Production

Skyepharma Production S.A.S. (Skyepharma) is a specialist CDMO with particular expertise and capabilities in oral solid dosage forms, being a key player in drug development and delivery of oral technologies serving the global pharmaceutical, biotech and consumer health industries.

Skyepharma is the oral business unit of the Vectura Group of companies, an international leader in inhalation and other drug delivery forms.

As an integrated CDMO, the company’s vision is to help solve healthcare industry complexity with a mission to provide a dedicated and results-oriented team to deliver advanced oral dosage services to the healthcare industry through state-of-the-art facilities, scientific expertise and open, transparent relationships. All of this is summed up in its strapline: ‘Expert and Agile CDMO partner for tailor-made solutions’.

The Skyepharma CDMO offer in solid oral dosage formats encompasses the whole value chain, including Formulation Development & Process Design, Analytical Development, Scale-up, Manufacturing, Packaging, Serialization and Aggregation.

Skyepharma also provides a range of support services that help client companies from early stage development (up to phase III), through scale-up and full commercial manufacturing and packaging to market introduction, including controlled substance handling, QbD methodology (FMEA, FTA, DOE), Troubleshooting, regulatory services, validation, registration and warehousing services.

About Vitafoods Europe 2019

The annual Vitafoods Europe conference and expo is the only dedicated event covering the entire nutraceutical supply chain – from ingredient to shelf – and provides a forum for the foods supplements industry to focus on creating innovation, networking with peers and finding effective solutions. The event showcases leading ingredients, raw materials, service or nutraceutical products from over 1,200 global suppliers. Vitafoods Europe.

Vitafoods Europe 2019 will particularly focus on sustainable ingredients and production with its new Sustainability Square located at the heart of the show, along fast-growing sectors like plant-based diets, hemp extracts and CBD. It will also feature a Clinical Trials Zone and Regulatory Clinic.

Vitafoods Europe 2019 is a three-day event opening May 7 at Geneva’s Palexpo Center and is expected to attract more than 22,000 visitors and 1,200 exhibitors from more than 110 countries worldwide.

The event is organized by Informa Exhibitions with further information at: https://www.vitafoods.eu.com/en/welcome.html

Media Contact

Perrine du Repaire, Sales & Marketing, Skyepharma S.A.S.
Tel: +33 4 74 95 20 46
Email: p.du.repaire@skyepharma.fr

Resources

Click on Skyepharma at Vitafoods Europe 2019 for other information.
Click on Skyepharma Production to contact the company directly.

Skyepharma will show Vitafoods Europe its capabilities to manufacture an almost limitless variety of food supplement and nutraceutical oral dosage forms

Skyepharma will show Vitafoods Europe its capabilities to manufacture an almost limitless variety of food supplement and nutraceutical oral dosage forms


Supplier Information
Supplier: Skyepharma Production S.A.S.
Address: Z.A. de Chesnes Ouest, 55 Rue du Montmurier – B.P. 45, 38291 Saint-Quentin-Fallavier, FRANCE
Tel: +33 4 74 95 20 4
Website: www.skyepharma.fr


Skyepharma achieved its transformation into an integrated, agile and expert CDMO, able to develop, manufacture and package complex oral solid forms


Skyepharma achieved its transformation into an integrated, agile and expert CDMO, able to develop, manufacture and package complex oral solid forms


Skyepharma Logo 150 x 43

Press Release |Skyepharma Production S.A.S.

APRIL 12, 2019

Saint-Quentin-Fallavier, France: – Over the past 36 months, oral dosage specialist Skyepharma Productions S.A.S. (Skyepharma) has undergone a significant and highly successful transformation with over €10 million in investments at its production site near Lyon in France.

Skyepharma has been transforming its processes and facilities to support its mission to become an end-to-end contract development and manufacturing organisation (CDMO), providing services extending from early stage development and manufacturing through to packaging, serialization and aggregation.

Major investments have been made to expand development and packaging. The company has invested in two brand new packaging lines for bottles and blisters and soon in a third packaging line for sachets.

Culture change

Skyepharma’s journey began in July 2016 and has been organised around four core strands of activity: culture change, pharmaceutical development growth, strong investments in industrial equipment and business development.

President of Skyepharma, David Lescuyer, has been reflecting on the changes in an interview by the online magazine PharmaBoardRoom.

Mr. Lescuyer told the magazine that the transformation had involved investment in new machinery, along with evolutions in the organization, corporate culture and embracing lean management practices across the company.

Faster time to market and API savings

“In Skyepharma, we have nurtured a strong culture based on respect, trust, performance, transparency, and team values not only internally but with our clients as well. The goal over these three years was about to establish an integrated organization where discussion and exchange are encouraged in daily operations. Since then, we have increased our team size by 20 professionals, including three PhDs, two pharmacists and many engineers,” said Mr. Lescuyer.

He said Skyepharma was able to enjoy comparative advantage within the CDMO sector through its distinctive ability to produce complex oral solid forms ranging from capsules, granules, tablets, and more. Through technological know-how, use of innovative compression simulators, technology transfer processes and in-house developed quality by design (QbD) disciplines; it could help clients reduce time to market.

Serialization and Aggregation opportunities

He said new regulations emphasizing serialization presented a major opportunity for Skyepharma.

“There will be a natural selection of players, between those who are prepared to meet the regulatory requirements and those which are not. Keeping up with the constantly increasing regulatory requirements allow us to offer up-to-date services to our partners. We have had for instance pharmaceutical companies approach us as they were unable to serialize or aggregate their products with their previous CMO partner.

“For Skyepharma, serialization and aggregation are very favorable entry doors to expand our client network and create new business activities, such as supply chain improvement projects,” said Mr. Lescuyer.

“We are uniquely positioned as a developer and producer of complex solid dosage forms with a distinct drug delivery platform and an agile proficiency to work alongside our partners and solve healthcare complexity,” Mr. Lescuyer concluded.

About Skyepharma Production

Skyepharma Production S.A.S. (Skyepharma) is a specialist CDMO with particular expertise and capabilities in oral solid dosage forms, being a key player in drug development and delivery of oral technologies serving the global pharmaceutical, biotech and consumer health industries.

Skyepharma is the oral business unit of the Vectura Group of companies, an international leader in inhalation and other drug delivery forms.

As an integrated CDMO, The company’s vision is to help solve healthcare industry complexity with a mission to provide a dedicated and results-oriented team to deliver advanced oral dosage services to the healthcare industry through state-of-the-art facilities, scientific expertise and open, transparent relationships. All of this is summed up in its strapline: ‘Expert and Agile CDMO partner for tailor-made solutions’.

The Skyepharma CDMO offer in solid oral dosage formats encompasses the whole value chain, including Formulation Development & Process Design, Analytical Development, Scale-up, Manufacturing, Packaging, Serialization and Aggregation.

Skyepharma also provides a range of support services that help client companies from early stage development (up to phase III), through scale-up and full commercial manufacturing and packaging to market introduction, including controlled substance handling, QbD methodology (FMEA, FTA, DOE), Troubleshooting, regulatory services, validation, registration and warehousing services.

Media Contact

Perrine du REPAIRE
Tel: +33 4 74 95 20 46
Email: partnership@skyepharma.fr

Resources

Click on Skyepharma transitions to full CDMO for more information.
Click on Skyepharma Production to contact the company directly.
Click on David Lescuyer interviewed by PharmaBoardroom to read the full article.


Supplier Information
Supplier: Skyepharma Production S.A.S.
Address: Z.A. de Chesnes Ouest, 55 Rue du Montmurier – B.P. 45, 38291 Saint-Quentin-Fallavier, FRANCE
Tel: +33 4 74 95 20 4
Website: www.skyepharma.fr